Abstract
The retrospective cost analysis estimates direct in-patient costs and length of stay (LOS) in hospital for acute heart failure (AHF). Patients were hospitalized with acute decompensation (ADHF) or de novo AHF in the Faculty Hospital Brno in 2005 and 2006. Burden incurred is divided to standard cardiology unit (SCU) and intensive care unit (ICU). In-patient care costs include flat rate of admission, stay and medicinal procedures. The pharmaceuticals are included in daily in-patient rate; angiography, revascularizations and antiarrhythmic interventions are calculated separately. In total, 734 patients (57% male, mean age 71.7 years) with AHF were analyzed. De novo AHF (58.6%) was more common than ADHF; according to the clinical classification AHF with mild signs and symptoms prevailed (46%). The overall direct hospital cost of all patients was €2.4 million, mean LOS was 8.3 days and mean in-patient cost was €3295 (including all interventions). Almost a half passed through both SCU and ICU with LOS 10.8 days; mean LOS in the SCU was 8.3 days with one-day cost of €55; mean LOS in the ICU was 3.4 days with one-day cost of €618. Total cost of cardiac catheterizations and revascularizations (50% patients) was almost a million; cost of antiarrhythmic interventions was €529216 (implantation of pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy with biventricular device; 6.9% patients). Mortality during hospitalization was 14.6%. AHF is associated with poor prognosis and high costs during hospital admission; the predominant contributors of high costs are revascularization procedures (39%), stay in the ICU (31%) and antiarrhythmic interventions (22%).
[1] The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26(11):1115–1140. 10.1093/eurheartj/ehi204Search in Google Scholar
[2] Spac J. Lecba chronickeho srdecního selhani u starsich nemocnych. (Chronic heart failure treatment in elderly). Medicina po promoci 2006;6:56. Search in Google Scholar
[3] Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208–225. 10.1093/oxfordjournals.eurheartj.a015223Search in Google Scholar
[4] The Task Force on Acute Heart Failure for the European Society of Cardiology. Executive summary of the guidelines on the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:384–416. 10.1093/eurheartj/ehi044Search in Google Scholar
[5] Spinar J, Jansky P, Kettner J, Malek I. Doporuceni pro diagnostiku a lecbu akutniho srdecniho selhani. (Recommendations for diagnosis and treatment of acute heart failure). Cor Vasa 2006;48:K3–K31. Search in Google Scholar
[6] Spinar J, Spinarova L, Vitovec J. The diagnosis, epidemiology, and prognosis of acute heart failure. Cor Vasa 2008;50 (4):171–175. 10.33678/cor.2008.057Search in Google Scholar
[7] Spinar J, Malek I. Lecba akutniho srdecniho selhani. (Managing acute heart failure). Cor Vasa 2008;50(4):177–182. 10.33678/cor.2008.058Search in Google Scholar
[8] Spinar J, Aschermann M, Al-Hiti H, Belohlavek J, Dusek L, Hlinomaz O, Kettner J, Linhart A, Malek I, Miklik R, Novak M, Parenica J, Vitovec J. Acute heart failure databases in specialist departments of cardiology. Cor Vasa 2008;50(1):12–21. 10.33678/cor.2008.012Search in Google Scholar
[9] Czech National Bank. Available from: http://www.cnb.cz Search in Google Scholar
[10] Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;6:693–700. Search in Google Scholar
[11] European Central Bank. ECB reference exchange rate, US dollar/Euro, 2:15 pm (C.E.T.). Available from: http://sdw.ecb.europa.eu/quickview.do?SERIES_KEY=120.EXR.D.USD.EUR.SP00.A Search in Google Scholar
[12] de Lissovoy G, Fraeman K, Mullahy J, et al. Hospital costs for treatment of acute heart failure: Economic analysis of Revive II study. Proceedings of the ISPOR 10th Annual European Congress; 2007 Oct 20–23; Dublin. Ireland: Value Health 2007;10(6):A412. 10.1016/S1098-3015(10)65438-1Search in Google Scholar
[13] de Lissovoy G, Fraeman K, Sterz R. Resource Use and Treatment Costs for Acute Decompensated Heart Failure: Economic Analysis of the SURVIVE Trial. Proceedings of the ISPOR 10th Annual European Congress; 2007 Oct 20–23; Dublin. Ireland: Value Health 2007;10(6):A415. 10.1016/S1098-3015(10)65448-4Search in Google Scholar
[14] Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725–2736. http://dx.doi.org/10.1093/eurheartj/ehl19310.1093/eurheartj/ehl193Search in Google Scholar PubMed
[15] Siirila-Waris K, Lassus J, Melin J, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006;27:3011–3017. http://dx.doi.org/10.1093/eurheartj/ehl40710.1093/eurheartj/ehl407Search in Google Scholar PubMed
[16] Institute of Health Information and Statistics of the Czech Republic. Deaths 2005. Available from: http://www.uzis.cz [Accessed November 30, 2006]. Search in Google Scholar
[17] Institute of Health Information and Statistics of the Czech Republic. Czech Health Statistics Yearbook 2005. Available from: http://www.uzis.cz [Accessed December 4, 2006]. Search in Google Scholar
[18] Institute of Health Information and Statistics of the Czech Republic. Czech Health Statistics Yearbook 2006. Available from: http://www.uzis.cz [Accessed November 15, 2007]. Search in Google Scholar
[19] McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596–602. http://dx.doi.org/10.1136/heart.83.5.59610.1136/heart.83.5.596Search in Google Scholar
[20] Berry C, Murdoch DR, McMurray JJV. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283–291. http://dx.doi.org/10.1016/S1388-9842(01)00123-410.1016/S1388-9842(01)00123-4Search in Google Scholar
[21] Haycox A, Bagust A. Pharmacoeconomics and clinical trials. In Walley T, Haycox A, Boland A. Pharmacoeconomics. Churchill Livingstone, Elsevier Science Limited, 2004. 203p. ISBN 0443 07240 X Search in Google Scholar
© 2009 Versita Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
